| Two phase 3 trials of dupilumab versus placebo in atopic dermatitis EL Simpson, T Bieber, E Guttman-Yassky, LA Beck, A Blauvelt, MJ Cork, ... New England Journal of Medicine 375 (24), 2335-2348, 2016 | 1795 | 2016 |
| Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies LF Eichenfield, WL Tom, TG Berger, A Krol, AS Paller, ... Journal of the American Academy of Dermatology 71 (1), 116-132, 2014 | 1576 | 2014 |
| Dupilumab treatment in adults with moderate-to-severe atopic dermatitis LA Beck, D Thaçi, JD Hamilton, NM Graham, T Bieber, R Rocklin, JE Ming, ... New England Journal of Medicine 371 (2), 130-139, 2014 | 1481 | 2014 |
| Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis LF Eichenfield, WL Tom, SL Chamlin, SR Feldman, JM Hanifin, ... Journal of the American Academy of Dermatology 70 (2), 338-351, 2014 | 1435 | 2014 |
| Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded … A Blauvelt, M de Bruin-Weller, M Gooderham, JC Cather, J Weisman, ... The Lancet 389 (10086), 2287-2303, 2017 | 1201 | 2017 |
| Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents R Sidbury, DM Davis, DE Cohen, KM Cordoro, TG Berger, JN Bergman, ... Journal of the American Academy of Dermatology 71 (2), 327-349, 2014 | 1199* | 2014 |
| Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention EL Simpson, JR Chalmers, JM Hanifin, KS Thomas, MJ Cork, ... Journal of Allergy and Clinical Immunology 134 (4), 818-823, 2014 | 882 | 2014 |
| Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health TE Shaw, GP Currie, CW Koudelka, EL Simpson Journal of Investigative Dermatology 131 (1), 67-73, 2011 | 879 | 2011 |
| Epidemiology of atopic dermatitis in adults: results from an international survey S Barbarot, S Auziere, A Gadkari, G Girolomoni, L Puig, EL Simpson, ... Allergy 73 (6), 1284-1293, 2018 | 803 | 2018 |
| Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose … D Thaci, EL Simpson, LA Beck, T Bieber, A Blauvelt, K Papp, W Soong, ... The Lancet 387 (10013), 40-52, 2016 | 629 | 2016 |
| Anti–interleukin-31 receptor A antibody for atopic dermatitis T Ruzicka, JM Hanifin, M Furue, G Pulka, I Mlynarczyk, A Wollenberg, ... New England Journal of Medicine 376 (9), 826-835, 2017 | 597 | 2017 |
| Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults AS Paller, WL Tom, MG Lebwohl, RL Blumenthal, M Boguniewicz, ... Journal of the American Academy of Dermatology 75 (3), 494-503. e6, 2016 | 556 | 2016 |
| Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study JI Silverberg, JM Gelfand, DJ Margolis, M Boguniewicz, L Fonacier, ... Annals of Allergy, Asthma & Immunology 121 (3), 340-347, 2018 | 555 | 2018 |
| Mental health comorbidity in patients with atopic dermatitis P Yaghmaie, CW Koudelka, EL Simpson Journal of Allergy and Clinical Immunology 131 (2), 428-433, 2013 | 547 | 2013 |
| Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2) A Wollenberg, A Blauvelt, E Guttman‐Yassky, M Worm, C Lynde, ... British Journal of Dermatology 184 (3), 437-449, 2021 | 446 | 2021 |
| Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial EL Simpson, AS Paller, EC Siegfried, M Boguniewicz, L Sher, ... JAMA dermatology 156 (1), 44-56, 2020 | 428 | 2020 |
| Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials EL Simpson, JP Lacour, L Spelman, R Galimberti, LF Eichenfield, ... British Journal of Dermatology 183 (2), 242-255, 2020 | 402 | 2020 |
| Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo … EL Simpson, R Sinclair, S Forman, A Wollenberg, R Aschoff, M Cork, ... The Lancet 396 (10246), 255-266, 2020 | 390 | 2020 |
| Conjunctivitis in dupilumab clinical trials B Akinlade, E Guttman‐Yassky, M de Bruin‐Weller, EL Simpson, ... British Journal of Dermatology 181 (3), 459-473, 2019 | 383 | 2019 |
| Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double … E Guttman-Yassky, HD Teixeira, EL Simpson, KA Papp, AL Pangan, ... The Lancet 397 (10290), 2151-2168, 2021 | 381 | 2021 |
